Findings

What do systematic reviews say?

10 questions · 11 findings · 7 reviews · Lung Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 9.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 45.5%Moderate 2 · 18.2%High 3 · 27.3%

TG4010 added to chemotherapy vs chemotherapy alone

Progression‐free survival · People with advanced non‐small cell lung cancer

TG4010 added to chemotherapy may leads to lower progression‐free survival compared with chemotherapy alone (low certainty).

1 finding from 1 review

Therapeutic vaccines for advanced non‐small cell lung cancer 2024 · Cochrane Headline outcomes only
HR 0.74 [0.55, 0.99]
1 study · 222 participants
Low

Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Progression‐free survival · People with advanced non‐small cell lung cancer

Single‐immune checkpoint inhibitors (ICIs) may leads to lower progression‐free survival (PFS) compared with chemotherapy (low certainty).

1 finding from 1 review

Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes only
HR 0.68 [0.51, 0.88]
5 studies · 1886 participants
Low

Combined immune checkpoint inhibitors (ICIs) vs chemotherapy alone

Progression‐free survival · People with advanced non‐small cell lung cancer

The review found no eligible studies for this question.

1 finding from 1 review

Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Afatinib vs chemotherapy alone

Progression‐free survival · EGFR M+ patients with NSCLC

Afatinib leads to lower progression‐free survival compared with chemotherapy (high certainty).

1 finding from 1 review

First‐line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non‐squamous non‐small cell… 2021 · Cochrane Headline outcomes only
HR 0.42 [0.34, 0.53]
2 studies · 709 participants
High

Gefitinib vs chemotherapy alone

Progression‐free survival · People with advanced non‐small cell lung cancer

Gefitinib showed no clear difference in progression‐free survival (PFS) compared with chemotherapy (moderate certainty).

2 findings from 1 review

Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
HR 1.19 [0.86, 1.65]
2 studies · 275 participants
Moderate
Gefitinib for advanced non‐small cell lung cancer 2018 · Cochrane Headline outcomes only
HR 1.04 [0.92, 1.17]
2 studies · 1607 participants
Moderate

Non‐platinum therapies vs platinum combination

Progression‐free survival · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to lower progression‐free survival compared with platinum combination (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
HR 0.76
9 studies · 9 participants
Low

Non‐platinum single‐agent vs non‐platinum combination treatment

Progression‐free survival · non‐small cell lung cancer in the elderly population

Non‐platinum single‐agent may leads to lower progression‐free survival compared with non‐platinum combination treatment (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
HR 0.94
4 studies · 1105 participants
Low

Intervention not reported

Progression‐free survival1 · Patients with advanced non‐small cell lung cancer

The intervention showed no clear difference in progression‐free survival1 (low certainty).

1 finding from 1 review

Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy‐naive advanced non‐small cell lung cancer 2014 · Cochrane Headline outcomes only
HR 0.91 [0.83, 1]
4 studies · 2018 participants
Low

ALK inhibitor vs any cytotoxic chemotherapy

Progression‐free survival · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

ALK inhibitor leads to lower progression‐free survival: all participants compared with any cytotoxic chemotherapy (high certainty).

1 finding from 1 review

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
HR 0.45 [0.4, 0.52]
6 studies · 1611 participants
High

ALK inhibitor vs any cytotoxic chemotherapy

Progression‐free survival in people with central nervous system disease · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

ALK inhibitor leads to lower progression‐free survival in people with central nervous system… compared with any cytotoxic chemotherapy (high certainty).

1 finding from 1 review

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
HR 0.51 [0.41, 0.62]
6 studies · 581 participants
High